PlainRecalls
FDA Devices Moderate Class II Ongoing

BD BBL Sensi Disc Levofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231705 and 231706¿

Reported: February 14, 2024 Initiated: January 8, 2024 #Z-1032-2024

Product Description

BD BBL Sensi Disc Levofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231705 and 231706¿

Reason for Recall

There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

Details

Recalling Firm
Becton Dickinson & Co.
Units Affected
2,363,168 total units
Distribution
Domestic distribution nationwide. International distribution worldwide.
Location
Sparks, MD

Frequently Asked Questions

What product was recalled?
BD BBL Sensi Disc Levofloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231705 and 231706¿. Recalled by Becton Dickinson & Co.. Units affected: 2,363,168 total units.
Why was this product recalled?
There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
Which agency issued this recall?
This recall was issued by the FDA Devices on February 14, 2024. Severity: Moderate. Recall number: Z-1032-2024.